Navigation Links
NIH awards $17 million Program of Excellence Award in glycosciences to Brigham and Women's Hospital
Date:7/7/2011

Boston, MA The laboratory of Robert Sackstein, MD, PhD, of the Dermatology Department at Brigham and Women's Hospital (BWH), has been granted a prestigious Program of Excellence Award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), to support investigations in glycobiology: the discipline which studies how sugars direct biologic processes. This particular Program of Excellence Award, the "Program of Excellence in Glycosciences" (PEG), is one of only five bestowed nation-wide, and provides more than $17 million of funding over a seven year period to support research in the lab of Dr. Sackstein and his collaborators.

"This award offers an unprecedented opportunity for the advancement of the discipline of glycobiology, and, commensurately, an immense opportunity for BWH, Harvard Medical School, and the greater Boston biomedical science community," said Dr. Sackstein, also an associate professor of dermatology and of medicine at Harvard Medical School. "Understanding glycobiology is at the core of explaining how cells in the body interact with each other, how they move in the body, how they lodge within tissue microenvironments, and how they grow and differentiate."

There is currently abundant evidence that sugar modifications of proteins and fats (lipids) regulate many of the biologic effects of these molecules. However, owing to a general lack of investigative expertise in sugar chemistry, especially among biomedical researchers, there has been relatively little work in elucidating how sugar modifications direct biologic processes. "The work that this Award supports is best represented by the term 'translational glycobiology,' as distinguished from 'glycosciences' and glycobiology,' because the ultimate goal is to obtain clinically translatable knowledge to improve the human condition," said Dr. Sackstein.

Dr. Sackstein's lab has pioneered the creation of novel tools and reagents to program discrete sugar modifications on the surface of live cells to achieve predetermined biologic effects. In a comprehensive multidisciplinary and interdisciplinary approach with collaborators Dr. Karen Hoffmeister, also of BWH, Dr. Joseph Lau, of Roswell Park Cancer Institute, and Dr. Vernon Rheinhold, of the University of New Hampshire, Dr. Sackstein's PEG project will specifically define how cell surface sugar modifications regulate blood cell production under both normal and pathologic conditions. The overarching goal of the program is to characterize the structure and function of certain sugars displayed on blood-forming cells, and thereby provide insights on how display of such sugars can be enforced to achieve therapeutic effects.

The PEG award was conceived and established by the NHLBI when current BWH President Elizabeth G. Nabel, MD, directed the institute. "Research in glycobiology has potential to advance patient care by improving blood cell development and treatments for blood diseases," said Dr. Nabel. "It is gratifying to see this translational work carried out at BWH."

Beyond funding critical research objectives, the Award also provides support for training investigators in glycobiology as well as support for key core resources for characterization and analysis of sugar modifications. With the express intent to provide the requisite investigative skills and resources to define how modulation of sugar modifications can advance needed breakthroughs in diagnosis, treatment and prevention of disease, the Award will thus spearhead the development of glycobiology at BWH and, more generally, at other research institutions of the northeast US.


'/>"/>

Contact: Holly Brown-Ayers
hbrown-ayers@partners.org
Brigham and Women's Hospital
Source:Eurekalert  

Related biology news :

1. Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists
2. Academic Press authors honored with awards
3. MARC Travel Awards announced for the 2011 Society for the Study of Reproduction Annual Meeting
4. MARC Travel Awards announced for the Society for Developmental Biology 70th Annual Meeting
5. Sandia captures 4 R&D 100 Awards
6. Los Alamos National Laboratory earns 3 R&D 100 Awards
7. ORNL researchers win 7 R&D 100 awards
8. Elsevier and ADSA announce winners of first annual Journal of Dairy Science Most Cited Awards
9. NSF awards CU-Boulder $5.9 million grant for alpine ecosystem research
10. MARC travel awards announced for the 25th Symposium of the Protein Society
11. MARC travel awards announced for the AAI 2011 Introductory Course in Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH awards $17 million Program of Excellence Award in glycosciences to Brigham and Women's Hospital
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology: